TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02650297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined decongestive therapy
Description: Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pneumatic compression pump
Description: Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
Study: NCT04643665

Intervention type: PROCEDURE
Intervention: Double-lung transplantation

Intervention type: PROCEDURE
Intervention: Double-lung transplantation
Study: NCT01705587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 20 microgram once-daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: 20 microgram once-daily subcutaneous injection
Study: NCT01280266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil or Amlodipine
Description: Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil or Amlodipine
Description: Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
Study: NCT03950999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sugar pill
Study: NCT01929213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Udenafil is administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan is administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil/Bosentan
Description: Udenafil and Bosentan are administered
Study: NCT00571688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperdal (risperidone) Consta
Description: Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score \> 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
Study: NCT00358501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
Study: NCT01319279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate extended-release tablet
Description: 15 mg (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone bitartrate extended-release tablet
Description: 15 mg (single dose)
Study: NCT03277508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI Robot Assisted Hand Therapy
Description: 18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).~Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.~Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.~Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM Robot Assisted Hand Therapy
Description: 18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
Study: NCT01768234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental water
Description: 1-2L of supplemental water provided between pre-test and post-test
Study: NCT02198651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Pre-filled syringe, administered by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
Study: NCT03618602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisthianostat
Description: Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisthianostat
Description: Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisthianostat
Description: Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisthianostat
Description: Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.
Study: NCT01769495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-3 day return appointment
Description: 2-3 appointment in geriatric clinic following ED discharge
Study: NCT01383109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled Pyronaridine
Description: Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
Study: NCT03525626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-based Tic Reduction
Description: 8-week online group mindfulness-based intervention for tics
Study: NCT04006080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Intravenously administered selective leukocyte adhesion molecule inhibitor
Study: NCT04186715

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: The Near-infrared spectroscopy probes will be placed in the frontal region.

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy
Description: The Near-infrared spectroscopy probes will be placed in the frontal region.
Study: NCT00888615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elesclomol Sodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT00082329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD 3100 (Mozobil plerixafor)
Description: Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
Study: NCT02801422

Intervention type: OTHER
Intervention: fMRI

Intervention type: OTHER
Intervention: fMRI
Study: NCT00957255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoADAPT
Description: soft tissue augmentation device
Study: NCT02514291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep intervention
Description: Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
Study: NCT00705770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate
Description: Low dose~Sustained release depot suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate
Description: Middle dose~Sustained release depot suspension
Study: NCT03080324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual
Description: Fentanyl sublingual

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl ev
Description: Fentanyl ev

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sublingual
Description: Placebo sublingual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ev
Description: Saline
Study: NCT04002622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT03826875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed fluoxetine and evaluated for the preventative treatment of depression and health-related quality-of-life

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients who suffered aneurysmal subarachnoid hemorrhage will be prescribed placebo and evaluated for the preventative treatment of depression and health-related quality-of-life
Study: NCT04592393

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Abbreviated PB MRI
Description: Annual non-contrast PB MRI.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene mutation test
Description: K-ras and GNAS mutation test. Being performed once as a baseline test at the enrollment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Conventional follow-up
Description: Any of followings: scheduled CECT, MRI, USG, EUS, tumor marker (CA 19-9) during the study period.
Study: NCT00180505

Intervention type: DEVICE
Group type: OTHER
Intervention: ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent
Description: A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
Study: NCT03855397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microneedle
Description: A microneedle patch (no drug) was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa to access pain, discomfort and safety.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypodermic needle
Description: 30 gauge hypodermic needle was inserted in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flat patch
Description: A flat patch was applied in the following oral cavity sites: lip, buccal, tongue, palatal and gingival mucosa.
Study: NCT01203995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition information
Description: Brief nutrition education with take home reference materials and portion size tools

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education and exercise training
Description: Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education and exercise training
Description: Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
Study: NCT04291092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy for brain metastasis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBRT
Description: local therapy for brain metastasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy for brain metastasis
Study: NCT03339115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovalve Transfemoral Mitral Valve
Description: The Cardiovalve Transfemoral Mitral Valve System is intended for use symptomatic patients with severe mitral regurgitation who are at elevated risk for surgical mitral valve repair or replacement and who are anatomically eligible for transfemoral mitral valve replacement with transseptal access to the left atrium.
Study: NCT03949101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 1 % Ophthalmic Ointment and Atropine Sulfate 0.01% Eye Drop
Description: use one drop into subconjunctiva

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine 0.01% eye drop
Description: use one drop into subconjunctiva
Study: NCT01957969

Intervention type: DEVICE
Intervention: Sacral Nerve Stimulation

Intervention type: DEVICE
Intervention: Sacral Nerve Stimulation
Study: NCT00995904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 84ug MAP0020
Description: 84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 84ug MAP0020
Description: 84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 84ug MAP0020
Description: 84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
Study: NCT00705770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate
Description: High dose~Sustained release depot suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment with vehicle
Study: NCT00995904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 84ug MAP0020
Description: 84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 84ug MAP0020
Description: 84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 84ug MAP0020
Description: 84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 42ug MAP0020
Description: 42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 42ug MAP0020
Description: 42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 42ug MAP0020
Description: 42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 42ug MAP0020
Description: 42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 42ug MAP0020
Description: 42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 42ug MAP0020
Description: 42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21ug MAP0020
Description: 21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21ug MAP0020
Description: 21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21ug MAP0020
Description: 21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21ug MAP0020
Description: 21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21ug MAP0020
Description: 21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21ug MAP0020
Description: 21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
Study: NCT01796236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive surgery and BA400
Description: The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional surgery and BA300
Description: The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
Study: NCT04062084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifunctional Cataract-assisted Retractor
Description: Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifunctional Cataract-assisted Retractor
Description: Multifunctional Cataract-assisted retractor operation for cataract with subluxation of lens
Study: NCT01251224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Pest Management
Description: The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: This group will receive education about mouse IPM.
Study: NCT03167736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electric dry needling, manipulation
Description: HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 12 treatment sessions over 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
Study: NCT03113630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition on TouchScreen
Description: Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition on Kinect
Description: Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acquisition on LeapMotion
Description: Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquisition on TouchScreen Control Group
Description: Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquisition on Kinect Control Group
Description: Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
Study: NCT00957255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care rotator cuff repair
Study: NCT02513771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
Study: NCT03113630

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acquisition on LeapMotion Control Group
Description: Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
Study: NCT03315481

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SAX catheter insertion
Description: Suture-method catheter inserted in the short axis of the adductor canal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAX catheter insertion
Description: Suture-method catheter inserted in the long axis of the adductor canal
Study: NCT02513771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for sitagliptin
Description: One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
Study: NCT04559269

Intervention type: OTHER
Intervention: No intervention
Description: patients have benefited from maintenance wakefulness tests as part of their clinical evaluation
Study: NCT03779061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Initial dose plus supplemental doses as necessary

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Initial dose plus supplemental doses as necessary